Clinical trial
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting…
NCT00261430 · Janssen, LP, Industry · Completed
Key facts
| NCT number | NCT00261430 |
|---|---|
| Title | A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone. |
| Official title | Schizophrenia Treatment Acceptance Response Trial: a 20-week, Open-label, Multicenter, Randomized Study Comparing the Effect of the "GAIN Acceptance Approach Verses the "Approach-as-usual" in Supporting Patient Acceptance of Long-acting Risperidone (Risperdal CONSTA) in Adults With Schizophrenia |
| Lead sponsor | Janssen, LP, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Behavioral |
| Interventions | GAIN Acceptance Approach |
| Enrollment | 650 |
| Completion | Oct 1, 2004 |
| First posted | Dec 5, 2005 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: